Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Bladder Cancer

  Free Subscription


29.01.2018

1 Acta Med Okayama
1 Biosensors (Basel)
1 BJU Int
1 Cancer Chemother Pharmacol
1 Cell Death Dis
1 Chin J Cancer
1 Clin Cancer Res
3 Clin Genitourin Cancer
1 Expert Rev Anticancer Ther
5 Gan To Kagaku Ryoho
1 Gastroenterology
4 Hinyokika Kiyo
1 Int J Cancer Manag
1 Int J Radiat Oncol Biol Phys
1 J Cancer Res Clin Oncol
1 J Cell Biochem
1 J Cell Mol Med
1 J Clin Invest
1 J Pak Med Assoc
1 J Transl Med
4 J Urol
1 Mol Cell Biochem
1 Oncogene
1 Oncogenesis
1 Pol J Pathol
1 Sci Rep
9 Transl Androl Urol
1 Urol Case Rep
1 Urol J
1 Urol Nurs
1 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Med Okayama

  1. SASAKI K, Wada K, Araki M, Kobayashi Y, et al
    Diagnostic Ureteroscopy for Cases Clinically Suspected of Carcinoma in Situ of the Upper Urinary Tract.
    Acta Med Okayama. 2017;71:227-232.
    PubMed     Text format     Abstract available


    Biosensors (Basel)

  2. GOGALIC S, Sauer U, Doppler S, Preininger C, et al
    Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer.
    Biosensors (Basel). 2018;8.
    PubMed     Text format     Abstract available


    BJU Int

  3. SEISEN T
    Examining the role of centralisation of radical cystectomy for bladder cancer.
    BJU Int. 2018;121:165-167.
    PubMed     Text format    


    Cancer Chemother Pharmacol

  4. BUTT SU, Malik L
    Role of immunotherapy in bladder cancer: past, present and future.
    Cancer Chemother Pharmacol. 2018 Jan 24. pii: 10.1007/s00280-018-3518.
    PubMed     Text format     Abstract available


    Cell Death Dis

  5. LIN ZR, Wang MY, He SY, Cai ZM, et al
    TACC3 transcriptionally upregulates E2F1 to promote cell growth and confer sensitivity to cisplatin in bladder cancer.
    Cell Death Dis. 2018;9:72.
    PubMed     Text format     Abstract available


    Chin J Cancer

  6. LI Y, Diao F, Shi S, Li K, et al
    Computed tomography and magnetic resonance imaging evaluation of pelvic lymph node metastasis in bladder cancer.
    Chin J Cancer. 2018;37:3.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  7. VAN KESSEL KE, van der Keur KA, Dyrskjot L, Algaba F, et al
    Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups.
    Clin Cancer Res. 2018 Jan 24. pii: 1078-0432.CCR-17-2719.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  8. NIWA N, Matsumoto K, Ide H, Nagata H, et al
    Prognostic Value of Pretreatment Albumin-to-Globulin Ratio in Patients With Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2018 Jan 4. pii: S1558-7673(18)30001.
    PubMed     Text format     Abstract available

  9. MINATO A, Fujimoto N, Kubo T
    Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
    Clin Genitourin Cancer. 2017;15:e1063-e1067.
    PubMed     Text format     Abstract available

  10. LEE CH, Ku JY, Jeong CW, Ku JH, et al
    Predictors for Intravesical Recurrence Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A National Multicenter Analysis.
    Clin Genitourin Cancer. 2017;15:e1055-e1061.
    PubMed     Text format     Abstract available


    Expert Rev Anticancer Ther

  11. SANLI O, Lotan Y
    Current approaches for identifying high-risk non-muscle invasive bladder cancer.
    Expert Rev Anticancer Ther. 2018 Jan 23. doi: 10.1080/14737140.2018.1432358.
    PubMed     Text format     Abstract available


    Gan To Kagaku Ryoho

  12. KIMURA G
    [IV .The Role of Immune Checkpoint Blockade in the Treatment of Bladder Cancer].
    Gan To Kagaku Ryoho. 2018;45:38-43.
    PubMed     Text format    

  13. MIYAZAKI J
    [III .Current Status of Bladder Preservation Therapy for Muscle Invasive Bladder Cancer].
    Gan To Kagaku Ryoho. 2018;45:33-37.
    PubMed     Text format    

  14. OZONO S, Furuse H
    [II .Problems of Treatment for Non-Muscle Invasive Bladder Cancer].
    Gan To Kagaku Ryoho. 2018;45:30-32.
    PubMed     Text format    

  15. ONOZAWA M
    [I .Recent Trends in Bladder Cancer Mortality in Japan].
    Gan To Kagaku Ryoho. 2018;45:26-29.
    PubMed     Text format    

  16. AKAZA H
    [Genitourinary Tumor Four Questions about Bladder Cancer].
    Gan To Kagaku Ryoho. 2018;45:25.
    PubMed     Text format    


    Gastroenterology

  17. HORVAT N, Ragucci M, Mannelli L
    Hepatic Mass in a Patient With Bladder Cancer History.
    Gastroenterology. 2018 Jan 16. pii: S0016-5085(17)35643.
    PubMed     Text format    


    Hinyokika Kiyo

  18. NITTA S, Sakka S, Endo T, Komine M, et al
    [Fever, Hepatic Dysfunction and Interstitial Pneumonia Caused by Intravesical Bacillus Calmette-Guerin (BCG) Instillation after Urethral Bougie : A Case Report].
    Hinyokika Kiyo. 2017;63:427-430.
    PubMed     Text format     Abstract available

  19. IKEUCHI R, Sunada T, Yoshikawa T, Yoshida T, et al
    [Reactive Arthritis during the Second Course of Intravesical BCG Therapy Requiring Administration of Methotrexate : A Case Report].
    Hinyokika Kiyo. 2017;63:329-332.
    PubMed     Text format     Abstract available

  20. MATSUMOTO Y, Waku N, Kawai K, Ikeda A, et al
    [A Case of Primary Schwannoma of the Urinary Bladder].
    Hinyokika Kiyo. 2017;63:323-328.
    PubMed     Text format     Abstract available

  21. OZAWA M, Kuromoto A, Morozumi K, Satou M, et al
    [Two Cases of Urachal Carcinoma Treated by TS-1/CDDP as Adjuvant Chemotherapy].
    Hinyokika Kiyo. 2017;63:413-419.
    PubMed     Text format     Abstract available


    Int J Cancer Manag

  22. BOTELHO MC, Alves H, Richter J
    Halting Schistosoma haematobium - associated bladder cancer.
    Int J Cancer Manag. 2017;10.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys


  23. Erratum to: Hafeez S, McDonald F, Lalondrelle S, et al. Clinical outcomes of image guided adaptive hypofractionated weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment. Int J Radiat Oncol Biol Phys 2017;98:115-122.
    Int J Radiat Oncol Biol Phys. 2018;100:532-533.
    PubMed     Text format    


    J Cancer Res Clin Oncol

  24. SANGUEDOLCE F, Cormio A, Massenio P, Pedicillo MC, et al
    Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer.
    J Cancer Res Clin Oncol. 2018 Jan 23. pii: 10.1007/s00432-018-2593.
    PubMed     Text format     Abstract available


    J Cell Biochem

  25. CORMICK BPM, Langle Y, Belgorosky D, Vanzulli S, et al
    Flavonoid Silybin improves the response to radiotherapy in invasive bladder cancer.
    J Cell Biochem. 2018 Jan 24. doi: 10.1002/jcb.26693.
    PubMed     Text format     Abstract available


    J Cell Mol Med

  26. JURACEK J, Peltanova B, Dolezel J, Fedorko M, et al
    Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer.
    J Cell Mol Med. 2018 Jan 24. doi: 10.1111/jcmm.13487.
    PubMed     Text format     Abstract available


    J Clin Invest

  27. HE W, Zhong G, Jiang N, Wang B, et al
    Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis.
    J Clin Invest. 2018 Jan 22. pii: 96218. doi: 10.1172/JCI96218.
    PubMed     Text format     Abstract available


    J Pak Med Assoc

  28. MITHANI MH, Khan SA, Khalid SE, Siddique R, et al
    Awareness of risk factors and fallacies associated with urinary bladder cancer in our population: A prospective survey.
    J Pak Med Assoc. 2018;68:55-58.
    PubMed     Text format     Abstract available


    J Transl Med

  29. ZHANG ZF, Zhang HR, Zhang QY, Lai SY, et al
    High expression of TMEM40 is associated with the malignant behavior and tumorigenesis in bladder cancer.
    J Transl Med. 2018;16:9.
    PubMed     Text format     Abstract available


    J Urol

  30. ATALA A
    Re: Mg(II)-Catechin Nanoparticles Delivering siRNA Targeting EIF5A2 Inhibit Bladder Cancer Cell Growth In Vitro and In Vivo.
    J Urol. 2017;198:258-259.
    PubMed     Text format    

  31. CHANG SS
    Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design.
    J Urol. 2017;198:255.
    PubMed     Text format    

  32. CHANG SS
    Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer.
    J Urol. 2018;199:341-342.
    PubMed     Text format    

  33. CHANG SS
    Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guerin.
    J Urol. 2018;199:340-342.
    PubMed     Text format    


    Mol Cell Biochem

  34. KHANDELWAL M, Anand V, Appunni S, Seth A, et al
    Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A.
    Mol Cell Biochem. 2018 Jan 24. pii: 10.1007/s11010-018-3278.
    PubMed     Text format     Abstract available


    Oncogene

  35. FANTINI D, Glaser AP, Rimar KJ, Wang Y, et al
    A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0099.
    PubMed     Text format     Abstract available


    Oncogenesis

  36. CHENG W, Fu D, Xu F, Zhang Z, et al
    Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
    Oncogenesis. 2018;7:2.
    PubMed     Text format     Abstract available


    Pol J Pathol

  37. POLETAJEW S, Wolinska E, Wasiutynski A, Dybowski B, et al
    [Immunohistochemical differentiation between muscularis mucosae and muscularis propria for improving the staging of bladder cancer in patients undergoing transurethral resection of bladder tumours].
    Pol J Pathol. 2017;68:218-224.
    PubMed     Text format     Abstract available


    Sci Rep

  38. CHU M, Zhang C
    Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer.
    Sci Rep. 2018;8:1539.
    PubMed     Text format     Abstract available


    Transl Androl Urol

  39. MARI A, D'Andrea D, Abufaraj M, Foerster B, et al
    Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.
    Transl Androl Urol. 2017;6:1081-1089.
    PubMed     Text format     Abstract available

  40. RIETHDORF S, Soave A, Rink M
    The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer.
    Transl Androl Urol. 2017;6:1090-1110.
    PubMed     Text format     Abstract available

  41. INEICHEN GB, Rothlisberger R, Johner KF, Seiler R, et al
    Different stages in drug development for muscle-invasive bladder cancer.
    Transl Androl Urol. 2017;6:1060-1066.
    PubMed     Text format     Abstract available

  42. PRADERE B, Thibault C, Vetterlein MW, Leow JJ, et al
    Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017.
    Transl Androl Urol. 2017;6:1049-1059.
    PubMed     Text format     Abstract available

  43. PANG KH, Esperto F, Noon AP
    Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction.
    Transl Androl Urol. 2017;6:1043-1048.
    PubMed     Text format     Abstract available

  44. DUQUESNE I, Weisbach L, Aziz A, Kluth LA, et al
    The contemporary role and impact of urine-based biomarkers in bladder cancer.
    Transl Androl Urol. 2017;6:1031-1042.
    PubMed     Text format     Abstract available

  45. RINK M
    The landscape of genetics and biomarkers in bladder cancer.
    Transl Androl Urol. 2017;6:1027-1030.
    PubMed     Text format    

  46. BUTTERFIELD A, Gupta S
    Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor.
    Transl Androl Urol. 2017;6:1198-1202.
    PubMed     Text format    

  47. WEZEL F, Vallo S, Roghmann F
    Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
    Transl Androl Urol. 2017;6:1067-1080.
    PubMed     Text format     Abstract available


    Urol Case Rep

  48. RODRIGUEZ LOPEZ S, Damas Arroyo F, Perez-Utrilla Perez MA, Lopez Sanchez D, et al
    Metastasis of Ta low-grade bladder cancer into the lung and paraneoplastic syndrome without local invasion: A case report and literature review.
    Urol Case Rep. 2017;17:17-18.
    PubMed     Text format    


    Urol J

  49. OUSATI ASHTIANI Z, Mehrsai AR, Pourmand MR, Pourmand GR, et al
    High Resolution Melting Analysis for Rapid Detection of PIK3CA Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy.
    Urol J. 2018 Jan 21. pii: 3987/1201.
    PubMed     Text format     Abstract available


    Urol Nurs

  50. BROUGHTON BL, Baron B, Kiernan M, Baack-Kukreja J, et al
    Cystectomy-Enhanced Recovery Program: Nursing Implications.
    Urol Nurs. 2017;37:9-14.
    PubMed     Text format     Abstract available


    World J Urol

  51. MOSCHINI M, Mattei A, Cornelius J, Shariat SF, et al
    Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy.
    World J Urol. 2018 Jan 24. pii: 10.1007/s00345-018-2190.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: